IL-7 gene-modified autologous melanoma cells

IL-7 gene-modified autologous melanoma cells are a personalized cellular immunotherapy where a patient’s own melanoma cells are genetically modified to express the cytokine **interleukin-7 (IL-7)**. This approach aims to enhance anti-tumor immune responses. Tumor cells are expanded from surgically resected metastases, transduced with the IL-7 gene using a ballistic gene transfer method, irradiated to prevent proliferation, and then injected subcutaneously as a vaccine. The **mechanism of action** is immunomodulation: the modified tumor cells secrete IL-7, which promotes T-cell proliferation and activation, boosting tumor-reactive, cytolytic, and proliferative immune cells. This product has primarily been studied in **phase I clinical trials for metastatic melanoma**, showing immunological changes but only minor clinical responses. The therapy is experimental and individualized for each patient, and no commercial developers or manufacturers are cited in published literature[1][2][5].

Brand names

IL-7 gene-modified autologous melanoma cellsIL7 gene-modified autologous melanoma cellsIL 7 gene-modified autologous melanoma cells

Other names

IL-7 gene-modified autologous melanoma cell vaccineIL7 gene-modified autologous melanoma cell vaccineIL 7 gene-modified autologous melanoma cell vaccineinterleukin 7 gene-modified autologous melanoma cell vaccineinterleukin7 gene-modified autologous melanoma cell vaccineinterleukin-7 gene-modified autologous melanoma cell vaccine